Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics firm Invitae has partnered with gene therapy developer Spark Therapeutics to launch a free genetic testing program for patients suspected of having inherited retinal disease (IRD).

In a separate deal, Invitae also partnered with X4 Pharmaceuticals to provide free genetic testing for WHIM syndrome and Severe Congenital Neutropenia (SCN), a group of rare inherited primary immunodeficiencies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.